Kalos Management’s Medifast MED Stock Holding History

Kalos Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32	Closed	-$3.32K	–	270
2023 Q1	$3.32K	Buy	+32	New	+$3.55K	0.01%	304

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Kalos Management's MED Position: Q2 2023 in Review

Kalos Management sold out of Medifast (MED) in Q2 2023, closing a stake of 32 shares — an estimated $3.32K sold.

Kalos Management first reported a position in MED in Q1 2023 and held it in 1 quarter. The position peaked at $3.32K in Q1 2023. 236 funds tracked by Wall St. Rank hold MED as of Q2 2023.

Kalos Management reported no remaining Medifast position as of Q2 2023 after selling out during the quarter.
Kalos Management sold 32 Medifast shares in Q2 2023, an estimated $3.32K.
Kalos Management first reported a position in Medifast in Q1 2023 and held it in 1 quarter.
Kalos Management's Medifast position peaked at $3.32K in Q1 2023.
236 funds tracked by Wall St. Rank held Medifast as of Q2 2023.

Based on Kalos Management's 13F filing for Q2 2023, filed 9 Aug 2023.